-
Azenta Prepares to Reveal Fiscal 2026 Financial Results
NASDAQ: $AZTA Mark Your Calendars for Azenta’s Fiscal Year-End Update Azenta, Inc. (Nasdaq: AZTA) has officially scheduled its conference call and webcast to discuss the company’s financial results for the fourth quarter and full fiscal year 2026. This event is a critical touchpoint for investors and stakeholders to gain insight into the company’s performance and…
-
Vanda Pharmaceuticals Sets Date for Q3 2026 Financial Results
NASDAQ: $VNDA Mark Your Calendars: Q3 2026 Financial Update Vanda Pharmaceuticals Inc. has officially announced that it will release its financial results for the third quarter of 2026 on Wednesday, October 28, 2026. This upcoming disclosure is a key event for investors and stakeholders looking to gauge the company’s performance throughout the quarter. How to…
-
CollPlant Biotechnologies Reports Q2 2026 Financial Results and Strategic Progress
NASDAQ: $CLGN Overview of Q2 2026 Financial Performance CollPlant Biotechnologies has officially released its financial results for the second quarter ending June 30, 2026, alongside a comprehensive corporate update. The company continues to advance its mission of transforming regenerative medicine through its proprietary plant-derived recombinant human collagen (rhCollagen) technology. Key Financial Highlights During the second…
-
Mark Your Calendars: Research Solutions Sets Q4 and Fiscal Year 2026 Earnings Date
NASDAQ: $RSSS Upcoming Financial Reporting Research Solutions, Inc. (NASDAQ: RSSS) has officially announced that it will release its financial results for the fourth quarter and fiscal year ended June 30, 2026. Investors and stakeholders should mark their calendars for the morning of Wednesday, September 9, 2026, when the company plans to share its performance metrics.…
-
Atrium Therapeutics Announces Q2 2026 Financial Performance
NASDAQ: $RNA Overview of Q2 2026 Results Atrium Therapeutics has officially released its financial results for the second quarter of 2026. As the company continues to navigate the complex biopharmaceutical landscape, these latest figures offer stakeholders a detailed look at the organization’s fiscal health and operational progress during the three-month period ending June 30, 2026.…
-
Illumina Announces Fourth Quarter and Fiscal Year 2025 Financial Performance
NASDAQ: $ILMN Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company reported solid performance across its core sequencing segments, reflecting continued momentum in both clinical adoption and research applications globally. Fourth Quarter Financial…
-
PTC Therapeutics Announces Date for Fourth Quarter and Full-Year 2025 Financial Results
NASDAQ: $PTCT PTC Therapeutics, a biotechnology company focused on developing innovative treatments for rare diseases, has officially announced the date for the release of its financial performance data for the fourth quarter and the entirety of the 2025 fiscal year. Investors, analysts, and stakeholders can anticipate the official announcement on Thursday, February 19, 2026. This…
-
Insmed to Present Fourth Quarter and Full Year 2025 Financial Results
NASDAQ: $INSM Insmed Incorporated has officially announced the schedule for its upcoming financial results presentation. The company will host a conference call to discuss its financial performance for the fourth quarter and the entirety of the fiscal year 2025. This event is set to take place on Thursday, February 19, 2026. The conference call is…
-
Viking Therapeutics Announces Q4 and Full-Year 2025 Financial Results Date
NASDAQ: $VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released…
-
Viatris Announces Q4 and Full-Year 2025 Financial Results Date and Investor Event Schedule
NASDAQ: $VTRS Viatris Inc. has officially announced the schedule for reporting its financial outcomes for the fourth quarter and the entirety of the 2025 fiscal year. This important update for investors and stakeholders is set for release on Thursday, February 26, 2026. Following the release of the comprehensive financial figures, Viatris will host a conference…
-
Amgen’s 2025 Financial Performance: A Review of Fourth Quarter and Full-Year Results
NASDAQ: $AMGN Amgen recently announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company’s performance reflects ongoing strategic initiatives and the impact of its evolving portfolio in the biotechnology sector. For the fourth quarter of 2025, Amgen reported total revenue of approximately $8.2 billion. This figure marks…